Network for Collaborative Oncology Development and Advancement Immunotherapy Hub: a centralized resource for navigating bispecific T-cell engagers
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/skrj5572 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Madelyn Floysand und 2 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
As of August 2025, ten bispecific T-cell engagers (BTCEs) have been approved in the United States for hematologic malignancies and solid tumors, with additional agents in development. These agents work by redirecting T cells to malignant cells by binding both a T-cell receptor and a tumor-associated antigen, creating a potent immune response. BTCEs are being studied in earlier therapy lines, expanding the eligible patient population. Their administration involves unique protocols, including step-up dosing to mitigate cytokine release syndrome (CRS) and monitoring for neurotoxicity such as immune effector cell–associated neurotoxicity syndrome (ICANS), which significantly impact care transitions. Certain BTCEs also carry Risk Evaluation and Mitigation Strategies (REMS) requirements. Practice settings vary, as some clinics manage all step-up doses outpatient while others partner with hospitals for toxicity management. Despite their growing use, many cancer centers lack tailored tools to support safe and efficient BTCE implementation. Available BTCE resources often provide broad overviews of these agents but are not tailored to operational realities.
Zitieren
APA
Floysand, M., Eugene, S., & Brunk, K. (2026). Network for Collaborative Oncology Development and Advancement Immunotherapy Hub: a centralized resource for navigating bispecific T-cell engagers. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/skrj5572
Vancouver
Floysand M, Eugene S, Brunk K. Network for Collaborative Oncology Development and Advancement Immunotherapy Hub: a centralized resource for navigating bispecific T-cell engagers. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/skrj5572
BibTeX
@article{Floysand2026,
author = {Floysand, Madelyn and Eugene, Shawnny and Brunk, Kelly},
title = {Network for Collaborative Oncology Development and Advancement Immunotherapy Hub: a centralized resource for navigating bispecific T-cell engagers},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/skrj5572}
}
EUVIMED